Практика лечения болевых синдромов
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Каратеев А.Е., Барскова В.Г. Критерии выбора нестероидного противовоспалительного препарата. Справ. практ. врача. 2007; 5 (5): 13–7.
2. Насонов Е.Л. Кардиоваскулярные осложнения ингибиторов ЦОГ-2 – вопросов больше, чем ответов. Рус. мед. журн. 2005; 13 (7): 383–91.
3. Насонов Е.Л., Каратеев А.Е. Приме- нение нестероидных противовоспалительных препаратов. Клинические рекомендации. Рус. мед. журн. 2006; 14 (25): 1769–77.
4. Boutsen Y, Esselinckx W. Novel nonsteroidal anti-inflammatory drugs. Acta Gastroenterol Belg 1999; 62 (4): 421–4.
5. DuBois RN, Abramson SB, Crofford L et al. Cyclooxygenase in biology and medicine. FASEB J 1998; 12: 1063–73.
6. Feldman M, McMahon AT. Do cyclooxigenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134–43.
7. Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinflamatory mediators: prostaglandins and nitric oxide. Clin Orthop 2004.
8. Goldring MB, Otero M, Tsuchimochi K et al. Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann rheum Dis 2008; 67 (Suppl III): 75–82.
9. Hawkey C, Kahan A, Steinbruck K et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937–45.
10. Peloso PM, Scheiman JM. The economic implications of cyclooxygenase2- specific inhibitors. Am J Med 2001; 110: 50S–54S.
11. Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal antiinflammatory drugs (NSAIDs). Am J Med 1999; 107 (6A): 27S–35S.
12. Silver DS The Use of COX-I-Sparing Agents in the Federal Health System. P&T 2004; 29 (7): 454–8.
13. Singh G, Triadafilopoulos G. Meloxicam has a low risk of serious gastrointestinal complications: Pooled analysis of 27,039 patients (Abstract SAT0085). European League Against Rheumatism (EULAR) 2001.
14. Wolfe M, Lichtenstein DR, Sinhg G. Gastrointestinal toxicity on nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 24: 1888–9.
15. Zeidler H, Kaltwasser JP, Leonard JP et al. Prescription and Tolerability of Meloxicam in Day-to-Day Practice: Postmarketing Observational Cohort Study of 13,307 Patients in Germany. J Clin Rheumatol 2002; 8 (6): 305–15.
2. Насонов Е.Л. Кардиоваскулярные осложнения ингибиторов ЦОГ-2 – вопросов больше, чем ответов. Рус. мед. журн. 2005; 13 (7): 383–91.
3. Насонов Е.Л., Каратеев А.Е. Приме- нение нестероидных противовоспалительных препаратов. Клинические рекомендации. Рус. мед. журн. 2006; 14 (25): 1769–77.
4. Boutsen Y, Esselinckx W. Novel nonsteroidal anti-inflammatory drugs. Acta Gastroenterol Belg 1999; 62 (4): 421–4.
5. DuBois RN, Abramson SB, Crofford L et al. Cyclooxygenase in biology and medicine. FASEB J 1998; 12: 1063–73.
6. Feldman M, McMahon AT. Do cyclooxigenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134–43.
7. Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinflamatory mediators: prostaglandins and nitric oxide. Clin Orthop 2004.
8. Goldring MB, Otero M, Tsuchimochi K et al. Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann rheum Dis 2008; 67 (Suppl III): 75–82.
9. Hawkey C, Kahan A, Steinbruck K et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937–45.
10. Peloso PM, Scheiman JM. The economic implications of cyclooxygenase2- specific inhibitors. Am J Med 2001; 110: 50S–54S.
11. Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal antiinflammatory drugs (NSAIDs). Am J Med 1999; 107 (6A): 27S–35S.
12. Silver DS The Use of COX-I-Sparing Agents in the Federal Health System. P&T 2004; 29 (7): 454–8.
13. Singh G, Triadafilopoulos G. Meloxicam has a low risk of serious gastrointestinal complications: Pooled analysis of 27,039 patients (Abstract SAT0085). European League Against Rheumatism (EULAR) 2001.
14. Wolfe M, Lichtenstein DR, Sinhg G. Gastrointestinal toxicity on nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 24: 1888–9.
15. Zeidler H, Kaltwasser JP, Leonard JP et al. Prescription and Tolerability of Meloxicam in Day-to-Day Practice: Postmarketing Observational Cohort Study of 13,307 Patients in Germany. J Clin Rheumatol 2002; 8 (6): 305–15.
Авторы
Л.Н.Малаховская
МУЗ Городская поликлиника №4, Омск
МУЗ Городская поликлиника №4, Омск
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.